Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients

被引:50
作者
Conil, Jean-Marie
Georges, Bernard
Mimoz, Olivier
Dieye, Eric
Ruiz, Stephanie
Cougot, Pierre
Samii, Kamran
Houin, Georges
Saivin, Sylvie
机构
[1] Hop Rangueil, Serv Reanim, F-31059 Toulouse 4, France
[2] Univ Poitiers, Poitiers, France
[3] Inst Federatif Biol, Lab Pharmacocinet & Toxicol Clin, Toulouse, France
[4] UPTE INRA ENVT, Fac Sci Pharmaceut Toulouse, Lab Cinet Xenobiot, UMR 181 Physiopathol & Toxicol Expt, Toulouse, France
[5] CHU Purpan, Fac Med Toulouse, Grp Rech Clin & Biol, Toulouse, France
关键词
piperacillin; appropriate antimicrobial therapy; critically ill patients; creatinine clearance;
D O I
10.1007/s00134-006-0421-1
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To explore the effects of renal function estimated by measured creatinine clearance (Cl-CR) on trough serum concentration (C-min) of piperacillin given to critically ill patients. Design: Prospective observational study. Setting: An intensive care unit and research ward in a university hospital. Patients: Seventy critically ill patients, including 22 with severe trauma. Interventions: All subjects received an intravenous infusion of piperacillin 4 g three times (n=61) or four times (n=9) per day. Piperacillin C-min values were determined 24 h after treatment started and compared to the French breakpoint defining antibiotic susceptibility against Enterobacteriaceae (8 mg/l) or Pseudomonas sp. (16 mg/l). Results: Median (range) piperacillin C-min was 11.9 (< 1-156.3) mg/l, with a great variability among patients. Although the median value was close to the breakpoints, sub-therapeutic plasma levels were frequently observed. Piperacillin C-min was lower than the breakpoint for Enterobacteriaceae in 37% of patients, and lower than the breakpoint for P. aeruginosa in 67% of them. A strong relationship was observed between piperacillin C-min and Cl-CR: the higher the Cl-CR, the lower the piperacillin C-min in serum. For patients with a Cl-CR < 50 ml/min, enough piperacillin C-min was achieved in most patients with 12 g piperacillin per day. For patients with higher Cl-CR values, a piperacillin daily dose of 16 g or more may be warranted. Conclusions: In critically ill patients, therapeutic monitoring must be part of the routine, and knowledge of Cl-CR value may be useful for the choice of adequate initial piperacillin dosing.
引用
收藏
页码:2063 / 2066
页数:4
相关论文
共 19 条
[1]   Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia [J].
Boselli, E ;
Breilh, D ;
Cannesson, M ;
Xuereb, F ;
Rimmelé, T ;
Chassard, D ;
Saux, MC ;
Allaouchiche, B .
INTENSIVE CARE MEDICINE, 2004, 30 (05) :976-979
[2]   RENAL-FUNCTION IN CRITICALLY ILL POSTOPERATIVE-PATIENTS - SEQUENTIAL ASSESSMENT OF CREATININE OSMOLAR AND FREE-WATER CLEARANCE [J].
BROWN, R ;
BABCOCK, R ;
TALBERT, J ;
GRUENBERG, J ;
CZURAK, C ;
CAMPBELL, M .
CRITICAL CARE MEDICINE, 1980, 8 (02) :68-72
[3]   Surgery and intensive care procedures affect the target site distribution of piperacillin [J].
Brunner, M ;
Pernerstorfer, T ;
Mayer, BX ;
Eichler, HG ;
Müller, M .
CRITICAL CARE MEDICINE, 2000, 28 (06) :1754-1759
[4]   Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion [J].
Buck, C ;
Bertram, N ;
Ackermann, T ;
Sauerbruch, T ;
Derendorf, H ;
Paar, WD .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 25 (01) :62-67
[5]   CONTINUOUS INFUSION OF BETA-LACTAM ANTIBIOTICS [J].
CRAIG, WA ;
EBERT, SC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (12) :2577-2583
[6]   Intermittent and continuous ceftazidime infusion for critically ill trauma patients [J].
Hanes, SD ;
Wood, GC ;
Herring, V ;
Croce, MA ;
Fabian, TC ;
Pritchard, E ;
Boucher, BA .
AMERICAN JOURNAL OF SURGERY, 2000, 179 (06) :436-440
[7]   THE IMPORTANCE OF PHARMACOKINETIC-PHARMACODYNAMIC SURROGATE MARKERS TO OUTCOME - FOCUS ON ANTIBACTERIAL AGENTS [J].
HYATT, JM ;
MCKINNON, PS ;
ZIMMER, GS ;
SCHENTAG, JJ .
CLINICAL PHARMACOKINETICS, 1995, 28 (02) :143-160
[8]   PENETRATION OF PIPERACILLIN-TAZOBACTAM INTO BRONCHIAL-SECRETIONS AFTER MULTIPLE DOSES TO INTENSIVE-CARE PATIENTS [J].
JEHL, F ;
MULLERSERIEYS, C ;
DELARMINAT, V ;
MONTEIL, H ;
BERGOGNEBEREZIN, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (12) :2780-2784
[9]   SINGLE-DOSE PHARMACOKINETICS OF PIPERACILLIN AND TAZOBACTAM IN PATIENTS WITH RENAL-DISEASE [J].
JOHNSON, CA ;
HALSTENSON, CE ;
KELLOWAY, JS ;
SHAPIRO, BE ;
ZIMMERMAN, SW ;
TONELLI, A ;
FAULKNER, R ;
DUTTA, A ;
HAYNES, J ;
GREENE, DS ;
KUYE, O .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (01) :32-41
[10]   Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection [J].
Li, CH ;
Kuti, JL ;
Nightingale, CH ;
Mansfield, DL ;
Dana, A ;
Nicolau, DP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (02) :388-395